PMV Pharmaceuticals Inc

PMV Pharmaceuticals Inc. is a clinical-stage oncology company developing small molecule therapies targeting p53 mutations. As a pharmaceutical developer, its research pipeline necessitates preclinical testing, which typically involves animal models. The company’s lead candidate, PC14586, is in clinical trials following standard preclinical development, a process that relies on animal testing for initial safety and efficacy data.

While the provided evidence does not detail PMV Pharmaceuticals' specific animal testing protocols, the broader pharmaceutical industry's standard practice is relevant. Preclinical testing for novel chemical entities, especially in oncology, is conducted in animal models as required by global regulatory authorities like the FDA for Investigational New Applications (INDs). The absence of a public commitment to alternative testing methods or a clear policy on animal welfare in its R&D indicates the company follows this conventional, animal-dependent pathway.

This exclusion is based on the company's operational category as a pharmaceutical developer, where animal testing is an inherent and material component of the drug discovery process. Specific evidence of the company's testing practices or a commitment to alternatives was not found in the provided materials.